Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2017, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. As of January 31, 2018, Global Cord Blood Corporation operates as a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).
Industry, Sector and Symbol
Industry Holding & other investment offices
Sub-IndustryN/A
SectorMedical
SymbolNYSE:CO
CUSIPN/A
Phone852-3605-8180
Debt
Debt-to-Equity RatioN/A
Current Ratio9.28
Quick Ratio9.20
Price-To-Earnings
Trailing P/E Ratio29.24
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$110.41 million
Price / Sales10.74
Cash Flow$0.3240 per share
Price / Cash30.34
Book Value$3.34 per share
Price / Book2.94
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$18.33 million
Net Margins27.05%
Return on Equity9.05%
Return on Assets4.49%
Miscellaneous
Employees1,059
Outstanding Shares120,610,000
Global Cord Blood (NYSE:CO) Frequently Asked Questions
What is Global Cord Blood's stock symbol?
Global Cord Blood trades on the New York Stock Exchange (NYSE) under the ticker symbol "CO."
How were Global Cord Blood's earnings last quarter?
Global Cord Blood Corp (NYSE:CO) posted its quarterly earnings results on Monday, August, 22nd. The medical research company reported $0.03 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.03. The medical research company had revenue of $26 million for the quarter, compared to the consensus estimate of $26.23 million. Global Cord Blood had a return on equity of 9.05% and a net margin of 27.05%. View Global Cord Blood's Earnings History.
When is Global Cord Blood's next earnings date?
Who are some of Global Cord Blood's key competitors?
Some companies that are related to Global Cord Blood include Alta Mesa Resources (AMR), TPG PACE ENERGY/SH CL A (TPGE), GTY Technology Holdings Inc Class A (GTYH), Vantage Energy Acquisition Corp Class A (VEAC), AgroFresh Solutions (AGFS), Pensare Acquisition (WRLS), Modern Media Acquisition (MMDM), FINTECH ACQUISI/SH (FNTE), KBL MERGER Corp/SH (KBLM), STELLAR ACQUISI/SH SH (STLR), TMSR (TMSR), JetPay (JTPY), UPD (UPDC), STG Group (STGG) and FCCC (FCIC).
Who are Global Cord Blood's key executives?
Global Cord Blood's management team includes the folowing people:
- Ms. Ting Zheng, Chairman, CEO & Interim CEO of Beijing Division (Age 46)
- Mr. Albert Chen, CFO, Chief Accounting Officer & Director (Age 42)
- Ms. Xin Xu, Chief Technology Officer (Age 64)
- Ms. Rui Arashiyama, Chief Exec. Officer of Guangdong Division & Zhejiang Division (Age 59)
Has Global Cord Blood been receiving favorable news coverage?
News headlines about CO stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Global Cord Blood earned a daily sentiment score of 0.19 on Accern's scale. They also assigned news stories about the medical research company an impact score of 46.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Global Cord Blood's major shareholders?
Global Cord Blood's stock is owned by a number of of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.14%), Citadel Advisors LLC (0.07%), Wells Fargo & Company MN (0.07%), California Public Employees Retirement System (0.05%), Parametrica Management Ltd (0.05%) and Dumac Inc. (0.02%). View Institutional Ownership Trends for Global Cord Blood.
Which institutional investors are selling Global Cord Blood stock?
Which institutional investors are buying Global Cord Blood stock?
CO stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Millennium Management LLC, Parametrica Management Ltd, Dumac Inc., Element Capital Management LLC, Citadel Advisors LLC, Cubist Systematic Strategies LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Global Cord Blood.
How do I buy shares of Global Cord Blood?
Shares of CO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Global Cord Blood's stock price today?
One share of CO stock can currently be purchased for approximately $9.83.
How big of a company is Global Cord Blood?
Global Cord Blood has a market capitalization of $1.20 billion and generates $110.41 million in revenue each year. Global Cord Blood employs 1,059 workers across the globe.
How can I contact Global Cord Blood?
Global Cord Blood's mailing address is 48TH FLOOR BANK OF CHINA TOWER 1 GARDEN ROAD, HONG KONG K3, . The medical research company can be reached via phone at 852-3605-8180 or via email at [email protected]
MarketBeat Community Rating for Global Cord Blood (CO)
MarketBeat's community ratings are surveys of what our community members think about Global Cord Blood and other stocks. Vote "Outperform" if you believe CO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CO will underperform the S&P 500 over the long term. You may vote once every thirty days.
